IPIrina Piatkov

Irina Piatkov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Irina Piatkov has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Dorgival Caetano

    University Clinic and Research Centre Blacktown, Western Sydney University, Western Sydney Local Health District, Blacktown, NSW, Australia

    3 shared publications
  • Dmitrii Shek

    Blacktown Clinical School, Western Sydney University, Sydney, NSW 2148, Australia

    1 shared publication
  • Golo Ahlenstiel

    Blacktown Clinical School and Research Centre, School of Medicine, Western Sydney University, Blacktown, Australia

    1 shared publication
  • Mark McLean

    University Clinic and Research Centre Blacktown, Western Sydney University, Western Sydney Local Health District, Blacktown, NSW, Australia

    1 shared publication
  • Scott A. Read

    Blacktown Clinical School, Western Sydney University, Blacktown, NSW 2148, Australia

    1 shared publication
  • Steven C Boyages

    University Clinic and Research Centre Blacktown, Western Sydney University, Western Sydney Local Health District, Blacktown, NSW, Australia

    1 shared publication

Latest Publications

  • Open Access

    Pharmacogenetics of anticancer monoclonal antibodies

    by Dmitrii Shek, Scott A. Read, Golo Ahlenstiel, Irina Piatkov

    Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.


  • Open Access

    ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine

    by Irina Piatkov, Dorgival Caetano, Yolinda Assur, Sue Lynn Lau, Trudi Jones, Steven C Boyages, Mark McLean

    Clozapine (CZ) has superior efficacy to other antipsychotic agents in the treatment of schizophrenia and has been extensively used in clinical practice. ATP-binding cassette (ABC) transporter proteins are responsible for the distribution of various molecules as well as drugs across extracellular and intracellular membranes, including the blood–brain barrier. Genetic variations in these proteins can account for differences in treatment response. We investigated the influence of ABCB1 rs1045642 and ABCC1 rs212090 single-nucleotide polymorphisms (SNPs) on CZ serum level, clinical outcome, and changes in body mass index (BMI) in the first year of CZ treatment. These polymorphisms influenced baseline BMI in males (p=0.009 and 0.054, B1 and C1, respectively), changes in BMI in males after 3 (p=0.026, ABCB1) and 12 months (p=0.022, ABCC1) of CZ treatment, and level of diastolic pressure (p=0.002 and 0.051, respectively). The combination of ABCB1 + ABCC1 homozygote SNPs was associated with increased CZ and norclozapine serum levels (p=0.054 and 0.010, respectively). ABC transporter SNPs could be potential biomarkers for CZ-induced weight gain and cardiovascular complications. Further pharmacogenetic research is warranted to help clinicians with their treatment decision, including concomitant use of drugs and prevention of side effects.


  • Open Access

    Serotonin Toxicity and Cytochrome p450 Poor Metaboliser Genotype Patient Case

    by Irina Piatkov

    Serotonin toxicity developed by patient with loss-of function Cytochrome P450 genetic polymorphisms' combination is described. Genotyping revealed CYP2D6, CYP2C19 and CYP1A2 non-functional polymorphisms previously associated with poor metaboliser phenotype. Inroduction Case A 28year-old female patient was admitted to the emergency department (ED) for anxiety and agitation including increased sweating of palms and restless legs. She had been treated with antidepressants by her general practitioner (GP) for 2years. Her medication was switched 2months previously and threeweeks prior to presentation to ED, her GP increased the fluoxetine dose from fluoxetine 20mg/day, to 40mg daily. On admission, the patient was confused, irritable, restless and agitated. Her physical examination was significant for tachycardia (122 beats/minute), hypertension (systolic BP 147 mmHg) and agitation. Neurologic examination was positive for hyperreflexia and clonus. She denied thoughts of selfharm, was compliant with medications, alert and orientated. Her background included smoking 10-15 cigarettes per day, and she had a family history of anxiety (both her mother and brother); she had no known allergies. Routine laboratory investigations were normal except for hypokalaemia (K). Serotonin toxicity was suspected and fluoxetine was ceased. Cyproheptadine 4mg and diazepam 5mg were administered to reduce agitation and serotonergic symptoms.


  • Ultrarapid Clozapine Metabolism andCYP2D6Gene Duplication in a Patient with Schizophrenia

    by Dorgival Caetano, Irina Piatkov

    An optimal clozapine serum level is required for both optimization of clinical response and minimization of troublesome or some of the life-threatening side effects. Serum levels can be influenced by comedication that can cause phenoconversion. When norclozapine/clozapine serum levels and ratios are consistently and significantly lower/higher than expected and there are no concomitant drugs that could account for these findings, further investigation of the genetic variants of CYP1A2, 2D6 and 3A4 are warranted.


  • Higher Than Expected Clozapine Serum Level and Clozapine/Norclozapine Ratio Due to Cyp450 Gene Polymorphisms

    by Dorgival Caetano, Irina Piatkov

    Aims: We investigated a case of the unexpectedly high clozapine/norclozapine serum levels in a non-smoker, female patient. Method: The RFLP genotype method was used for the loss-of-function CYP450 gene polymorphisms detection. Results: The genotype revealed the presence of CYP2D6*41/*41, rs28371725, NM_000106.5:c.985+39G>A and CYP1A2*1/*1D rs35694136, NM_000761.4:c.-1635delT. Conclusion: An appropriate clozapine serum level is required for both optimization of clinical response and avoidance of troublesome, or even life-threatening side effects. Although not the only factor, genetic polymorphisms responsible for the metabolism of clozapine play an important role towards such goals. Pharmacogenetic tests can guide dose adjustment in order to obtain an optimum serum level, which can lead to a better therapeutic response and minimization of harmful side effects.